Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thermogenesis and weight control.

T T Yen, M M McKee, N B Stamm

    International Journal of Obesity
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Compound LY104119 acts as a potent beta-agonist, effectively reducing body weight in obese mice by stimulating the beta-adrenergic system and increasing thermogenesis. Metabolic responses were similar across obese and normal mice, with differences attributed to food consumption compensation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene.

    Oncogene·1999
    Same author

    Monoclonal antibodies as surrogate receptors in a high throughput screen for compounds that enhance insulin sensitivity.

    Life sciences·1997
    Same author

    Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents.

    Obesity research·1995
    Same author

    Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.

    Obesity research·1994
    Same author

    Dexamethasone-induced hyperglycemia in obese Avy/a (viable yellow) female mice entails preferential induction of a hepatic estrogen sulfotransferase.

    Diabetes·1994
    Same author

    Pancreatic islet cells in preobese yellow Avy/- mice: relation to adult hyperinsulinemia and obesity.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·1994
    Same journal

    Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity.

    International journal of obesity·1991
    Same journal

    Sonography detection of small intra-abdominal fat variations.

    International journal of obesity·1991
    Same journal

    Obesity surgery: expectation and reality.

    International journal of obesity·1991
    Same journal

    Relationships between the amount of weight loss and post-heparin lipoprotein lipase activity in patients with type II diabetes.

    International journal of obesity·1991
    Same journal

    The individual and combined effects of cigarette smoking and food on resting energy expenditure.

    International journal of obesity·1991
    Same journal

    Oxygen consumption of muscles from ob/ob and Ay/a strains of obese mice.

    International journal of obesity·1991
    See all related articles

    Area of Science:

    • Pharmacology
    • Metabolic Research
    • Obesity Studies

    Background:

    • Obesity is a complex metabolic disorder with significant health implications.
    • Beta-adrenergic agonists have shown potential in modulating energy expenditure and body weight.
    • Understanding the mechanisms of weight regulation is crucial for developing effective anti-obesity strategies.

    Purpose of the Study:

    • To investigate the pharmacological effects of compound LY104119, a novel beta-agonist.
    • To evaluate the efficacy of LY104119 in reducing body weight in obese mouse models.
    • To elucidate the metabolic and thermogenic responses to LY104119 treatment.

    Main Methods:

    • In vitro and in vivo assays to assess beta-receptor binding affinity (Ki).
    • Measurement of cyclic AMP levels, lipolysis, and CO2 expiration.

    Related Experiment Videos

  • Administration of LY104119 via subcutaneous, oral, and dietary routes in obese (Avy/a) and normal (a/a) mice.
  • Assessment of body weight, food consumption, triacylglycerol levels, and thermogenesis.

    • Main Results:

    • LY104119 demonstrated potent beta-agonist activity, comparable to isoproterenol.
    • Treatment with LY104119 reduced body weight in obese mice by stimulating lipolysis and increasing thermogenesis.
    • Obese mice showed reduced food consumption, while normal mice compensated for energy loss with increased food intake.
    • LY104119 normalized elevated hepatic glucokinase activity in obese mice and reduced beta-receptor density in lung membranes.

    Conclusions:

    • Compound LY104119 effectively decreases body weight in obese mice through beta-adrenergic system stimulation.
    • Metabolic responses to LY104119 are consistent between obese and normal mice.
    • The differential effect on weight management is linked to the capacity of mice to modulate food intake in response to energy expenditure.